{
  "id": "mhgap#screening_cues_823100af",
  "content": "Remarks\nschizophrenia) (191); Kishi et al. 2019 (10 RCTs on\ny Discontinuation of antipsychotics should always be\ndiscontinuation versus maintenance of antipsychotic\ndone by gradually and slowly reducing the medicine\nmedicines in schizophrenia) (194); and Schneider-\ndose. When medicines are discontinued, people\nThoma et al., 2018 (596 RCTs on second-generation\nliving with schizophrenia and family members\nantipsychotic medicines and short-term somatic\nneed to be educated to detect the re-emergence of\nserious adverse events in individuals with severe\nsymptoms early to allow for close clinical monitoring\nmental illness) (193).\nof relapse.\ny Maintenance therapy was significantly superior to\ndiscontinuation with a follow-up of up to 12 months\nas well as up to 24 months. However, antipsychotics\nwere associated with side-effects.\n89\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nResearch gaps newer antipsychotics may have higher costs than\ny Most of the evidence is from HICs. Further research is older first-generation antipsychotics.\nneeded in LMICs. y Interruptions in medicine availability (common\ny There was no evidence for maintenance therapy in LMICs and in supply chain interruption such\nfor more than two years and evidence was scarce as during emergencies) may interfere with",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "relationships",
      "screening_cues",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Screening Cues Remarks\nschizophrenia) (191); Kishi et al. 2019 (10 RCTs on\ny Discontinuation of antipsychotics should always be\ndiscontinuation versus maintenance of antipsychotic\ndone by gradually and slowly reducing the medicine\nmedicines in schizophrenia) (194); and Schneider-\ndose. When medicines are discontinued, people\nThoma et al., 2018 (596 RCTs on second-generation\nliving with schizophrenia and family members\nantipsychotic medicines and short-term somatic\nneed to be educated to detect the re-emergence of\nserious adverse events in individuals with severe\nsymptoms early to allow for close clinical monitoring\nmental illness) (193).\nof relapse.\ny Maintenance therapy was significantly superior to\ndiscontinuation with a follow-up of up to 12 months\nas well as up to 24 months. However, antipsychotics\nwere associated with side-effects.\n89\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nResearch gaps newer antipsychotics may have higher costs than\ny Most of the evidence is from HICs. Further research is older first-generation antipsychotics.\nneeded in LMICs. y Interruptions in medicine availability (common\ny There was no evidence for maintenance therapy in LMICs and in supply chain interruption such\nfor more than two years and evidence was scarce as during emergencies) may interfere with Remarks\nschizophrenia) (191); kishi et al. 2019 (10 rcts on\ny discontinuation of antipsychotics should always be\ndiscontinuation versus maintenance of antipsychotic\ndone by gradually and slowly reducing the medicine\nmedi..."
}